Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company d...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Website: www.tonixpharma.com

Address:

200 Connell Drive, Suite 3100, Berkeley Heights, United States

i8j0momma666 Sep. 21 at 1:26 AM

$TNXP

0 · Reply

JRoc16 Sep. 20 at 11:44 PM

$TNXP Here's to a better week ahead Bulls !

0 · Reply

StarJ7 Sep. 20 at 2:41 PM

$TNXP

0 · Reply

JuggernautRaider Sep. 19 at 4:58 PM

$TNXP how Seth is still an active CEO boggles my simple American shareholder mind 🤢 🤮 🇺🇸 PROMOTE THE COO AND FIRE SETH! 🏦 DOCTOR LEADER MAN? Anything BUT! 🥾 👢 Screw Seth! HE SUCKS AT HIS JOB! 👋 🌊 https://www.tonixpharma.com/jessica-morris/ ⬅️ 🗳️

3 · Reply

Willy_Nilly Sep. 19 at 4:14 PM

$TNXP @JuggernaughtRaider thanks brother for that update.. just some food for thought as Trx continues it's climb albeit w some minor fluctuations... The company didn't need January Medicaid/Medicare expansion to get here. It didn't need the full impact of the expanded sales force to get here. It got from: 525 → 1,005 TRx during the period when access and commercial infrastructure were still developing. Good things are happening.. patients are trying and STAYING w Tonmya.

3 · Reply

lifelearner Sep. 19 at 5:08 AM

$TNXP If you followed this stock for several years, you must have seen 50x, 100x target prices on Yahoo all those times. It never ever happened and had continuous disappontments of reverse splits, offerings, and ATMs instead.

0 · Reply

Jake_DayTrades Sep. 19 at 2:03 AM

$TNXP 193 instiutions are long 5 or short

1 · Reply

glbeacher Sep. 19 at 12:45 AM

$TNXP why such high volume today

2 · Reply

XP05B18801 Sep. 18 at 11:52 PM

$TNXP Sathan loves you. Your are part of his flock. No reasonable understanding on output versus profitable results. Bubble gum to wall.

0 · Reply

TOOKPROFITS Sep. 18 at 11:19 PM

$TNXP Yahoo has been out of the loop since the 90s playa

1 · Reply

Tonix Pharmaceuticals Holding Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

2026-09-08T11:30:46.000Z - 12 days ago

Tonix Pharmaceuticals promotes Thomas Englese to chief commercial officer

Sep 8, 2026, 7:00 AM EDT - 12 days ago

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

Sep 2, 2026, 8:00 AM EDT - 18 days ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Sep 2, 2026, 7:00 AM EDT - 18 days ago

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

Aug 11, 2026, 1:30 PM EDT - 5 weeks ago

Tonix Pharmaceuticals Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-10T17:55:08.000Z - 5 weeks ago

Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James

Aug 10, 2026, 8:30 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Holding Earnings Call Transcript: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Holding Earnings release: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Holding Quarterly report: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Holding Slides: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Aug 5, 2026, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

2026-08-03T11:56:09.000Z - 6 weeks ago

Tonix Pharmaceuticals receives Type C meeting minutes from FDA for TNX-4800

Aug 3, 2026, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Aug 3, 2026, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jul 27, 2026, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

Jul 20, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Slides: Corporate presentation

Jul 16, 2026, 8:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jul 15, 2026, 9:05 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

2026-07-13T11:15:17.000Z - 2 months ago

Tonix Pharmaceuticals announces managed Medicare agreement for Tonmya

Jul 13, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

Jul 1, 2026, 8:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-06-29T11:40:14.000Z - 2 months ago

Tonix Pharmaceuticals enrolls first patient in HORIZON study

Jun 29, 2026, 7:25 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

2026-06-24T20:36:04.000Z - 2 months ago

Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James

Jun 15, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jun 11, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

2026-06-08T11:14:39.000Z - 3 months ago

Tonix Pharmaceuticals secures second commercial agreement for Tonmya

Jun 8, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Jun 1, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-05-28T21:29:12.000Z - 3 months ago

Tonix presents data from analysis of opioid use in adults with fibromyalgia

May 28, 2026, 4:30 PM EDT - 3 months ago

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

2026-05-27T13:00:38.000Z - 3 months ago

Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology

May 27, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

May 27, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-05-26T11:57:59.000Z - 3 months ago

Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia

May 26, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

May 19, 2026, 1:35 PM EDT - 4 months ago

Tonix Pharmaceuticals Holding Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 17, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Slides: 2nd Richard Slayman Clinical Xenotransplantation Workshop presentation

May 14, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

May 12, 2026, 4:30 PM EDT - 4 months ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

2026-05-11T23:47:32.000Z - 4 months ago

Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year

May 11, 2026, 4:30 PM EDT - 4 months ago

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

May 11, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Earnings release: Q1 2026

2026-05-07T04:37:07.000Z - 4 months ago

Tonix Pharmaceuticals secures commercial payer coverage for Tonmya

May 6, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

2026-05-04T09:45:07.000Z - 4 months ago

Tonix Pharmaceuticals initiated with a Buy at TD Cowen

2026-04-29T15:52:42.000Z - 4 months ago

Tonix Pharmaceuticals says on track to initiate Phase 2 study of TNX-4800

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University

Apr 23, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

2026-04-15T11:14:23.000Z - 5 months ago

Tonix Pharmaceuticals publishes Tonmya study data findings

Apr 15, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

Apr 7, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-03-31T11:25:26.000Z - 5 months ago

Tonix Pharmaceuticals presents TNX-4800 data, to initiate adaptive field study

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Slides: Corporate presentation

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Mar 24, 2026, 8:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Holding Slides: Conference presentation

Mar 23, 2026, 4:32 PM EDT - 6 months ago

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Mar 20, 2026, 8:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

Mar 18, 2026, 4:58 PM EDT - 6 months ago

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Mar 17, 2026, 4:35 PM EDT - 6 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 12, 2026, 5:30 PM EDT - 6 months ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Holding Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Holding Annual report: Q4 2025

Mar 11, 2026, 1:00 PM EDT - 6 months ago

Tonix Pharmaceuticals Holding Transcript: Life Sciences Virtual Investor Forum

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Mar 9, 2026, 4:30 PM EDT - 6 months ago

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 4:30 PM EDT - 6 months ago

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Mar 5, 2026, 4:15 PM EST - 6 months ago

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Mar 4, 2026, 11:10 AM EST - 6 months ago

Tonix Pharmaceuticals Holding Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 4:30 PM EST - 6 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

Mar 3, 2026, 6:00 AM EST - 6 months ago

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Feb 25, 2026, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Jan 30, 2026, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Jan 6, 2026, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Dec 29, 2025, 7:57 AM EST - 8 months ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Dec 29, 2025, 7:45 AM EST - 8 months ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Dec 16, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Dec 9, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Nov 24, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Nov 17, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Nov 13, 2025, 10:00 AM EST - 10 months ago

Tonix Pharmaceuticals Holding Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 10:00 AM EST - 10 months ago

Tonix Pharmaceuticals Holding Slides: FY 2025

Nov 10, 2025, 4:15 PM EST - 10 months ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 10, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals Holding Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals Holding Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 10 months ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Oct 28, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 27, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 22, 2025, 7:00 AM EDT - 11 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 21, 2025, 7:00 AM EDT - 11 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 17, 2025, 7:00 AM EDT - 11 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

i8j0momma666 Sep. 21 at 1:26 AM

$TNXP

0 · Reply

JRoc16 Sep. 20 at 11:44 PM

$TNXP Here's to a better week ahead Bulls !

0 · Reply

StarJ7 Sep. 20 at 2:41 PM

$TNXP

0 · Reply

JuggernautRaider Sep. 19 at 4:58 PM

3 · Reply

Willy_Nilly Sep. 19 at 4:14 PM

3 · Reply

lifelearner Sep. 19 at 5:08 AM

0 · Reply

Jake_DayTrades Sep. 19 at 2:03 AM

$TNXP 193 instiutions are long 5 or short

1 · Reply

glbeacher Sep. 19 at 12:45 AM

$TNXP why such high volume today

2 · Reply

XP05B18801 Sep. 18 at 11:52 PM

$TNXP Sathan loves you. Your are part of his flock. No reasonable understanding on output versus profitable results. Bubble gum to wall.

0 · Reply

TOOKPROFITS Sep. 18 at 11:19 PM

$TNXP Yahoo has been out of the loop since the 90s playa

1 · Reply

TOOKPROFITS Sep. 18 at 11:16 PM

$TNXP YES MUDDA FCKA YES

0 · Reply

StavStocks Sep. 18 at 8:47 PM

$TNXP

0 · Reply

Terminator11 Sep. 18 at 8:41 PM

$TNXP did the dump at the end

0 · Reply

C4Trading Sep. 18 at 8:19 PM

$TNXP Insane volume spike the last 20 minutes. I'll buy more $10 shares thanks.

1 · Reply

ByBi Sep. 18 at 8:15 PM

$TNXP opportunity cost is heavy i'll liquidate and buy back at 8 or 9 i got to be paid too

0 · Reply

B13UNE Sep. 18 at 8:10 PM

$TNXP im shocked that this comm is even MORE deluded than the folk on T212, stock is going nowhere

0 · Reply

LUKAN88 Sep. 18 at 8:03 PM

$TNXP ALL IS POSSIBLE

0 · Reply

TheUnmaker Sep. 18 at 8:00 PM

$TNXP Now we wait for the $10.69 gap fill next week and see what it does.

1 · Reply

TheUnmaker Sep. 18 at 7:51 PM

$TNXP el oh el - predictable... next week we go to $10.35

0 · Reply

JustAguysOpinion Sep. 18 at 7:51 PM

$TNXP It's a preventative do your research. Also people with jobs have insurance. Who would want it? People like outdoor a tivities in woods. Hunters, hikers, campers and such.

0 · Reply

XP05B18801 Sep. 18 at 7:34 PM

$TNXP Out of the 81k thread liner here how many will line up at CVS to get their expensive two dose course of Sathans Lyme Vaccine? This what he spending stakeholders money on. % of US population that caught Lyme disease .00136%. Remember for profit company. Not R&D institute.

1 · Reply

pickles14 Sep. 18 at 7:30 PM

$TNXP - I like Yahoo’s 1yr target estimate. 1y Target Est 44.50

1 · Reply

Market Cap	186.43M
Revenue (ttm)	13.11M
Net Income (ttm)	-124.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-946.00%
Debt to Equity Ratio	0.00

Volume	808,400
Avg Vol	478,750
Day's Range	N/A - N/A
Shares Out	17.15M
Stochastic %K	3%
Beta	1.74
Analysts	Strong Sell
Price Target	$42.40